HOOKIPA Biotech GmbH
Hookipa Biotech GmbH
Helmut-Qualtinger-Gasse 2
Vienna
1030
Austria
Website: http://www.hookipapharma.com/
About HOOKIPA Biotech GmbH
62 articles about HOOKIPA Biotech GmbH
-
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
4/24/2024
HOOKIPA Pharma Inc. announced that the Company has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers.
-
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
1/16/2024
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced the appointment of Mark Winderlich, PhD, as Chief Development Officer, effective April 1, 2024.
-
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
11/9/2023
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported financial results and business highlights for the third quarter of 2023.
-
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
11/2/2023
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023.
-
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
10/22/2023
HOOKIPA Pharma Inc. presented updated data from its ongoing Phase 2 trial of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic Human Papillomavirus 16-positive head and neck cancer.
-
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 10, 2023
6/10/2023
HOOKIPA Pharma Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to new employees to purchase an aggregate of 80,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan.
-
HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference
4/19/2023
HOOKIPA Pharma Inc. announced that the company will participate in investor meetings at the Van Lanschot Kempen Life Sciences Conference being held in Amsterdam, April 25 - 26, 2023.
-
HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference
11/2/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the company will participate in the Sidoti Micro-Cap Virtual Conference, November 9 - 10, 2022.
-
Roche and Austria-based Hookipa Pharma tied up a licensing and research and development collaboration valued at more than $950 million focused on KRAS-mutated cancers.
-
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
8/11/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapies based on its proprietary arenavirus platform, reported financial results for the second quarter of 2022 and Company updates.
-
FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
7/25/2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, has received U.S. Food and Drug Administration (FDA) acceptance of its Investigational New Drug (IND) application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.
-
There were multiple leadership changes in the biopharma industry, with several new chief executive officers tapped to guide companies through their next growth phases.
-
HOOKIPA Announces Executive Leadership Changes
6/21/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced several leadership changes as the company expands its clinical development and pipeline programs.
-
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
6/5/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced positive Phase 1 results from its HB-200 program evaluating single-vector HB-201 and alternating 2-vector HB-202/HB-201 in advanced Human Papillomavirus 16-positive head and neck cancer patients.
-
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
6/3/2022
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting.
-
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
5/26/2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), today announced that complete HB-200 Phase 1 results (NCT04180215) for single-vector HB-201 and alternating 2-vector HB-202/HB-201 in patients with advanced Human Papillomavirus 16-positive (HPV16+) cancers, including the recommended Phase 2 dose for HB-202/HB-201, will be shared in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights
5/16/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported financial results and business highlights for the first quarter of 2022.
-
HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022
5/9/2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial results before the market open on Monday, May 16, 2022.
-
BioSpace Movers & Shakers, May 6
5/6/2022
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May 2022
5/3/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that HOOKIPA’s management team will participate in and present at the following upcoming investor conferences: